Matches in SemOpenAlex for { <https://semopenalex.org/work/W2621439852> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2621439852 abstract "Background and Objectives The addition of an inhaled long-acting ?2-agonist (LABA) to an inhaled corticosteroid (ICS) gives optimal control of asthma in most patients. The LABA salmeterol xinafoate (salmeterol) with inhaled corticosteroid (ICS) fluticasone propionate (fluticasone) and formoterol with budesonide are available as a combination product pMDI in a single aerosol inhaler. This study compared the efficacy and safety of commercially available salmeterol/fluticasone with formeterol/budesonide. Materials and Methods Patients aged >12 years inclusive of either sex (N = 40) with persistent asthma as defined by NHLBI for >6 months prior to screening were included in the study. After a screening phase (1 week), eligible patients were enrolled in the study with 2 weeks run-in period. Eligible patients were randomized to receive either of the two treatment groups [HFA-propelled pMDI salmeterol/fluticasone (50/100 mcg) or HFApropelled formoterol/budesonide (6/100 mcg) pMDI] in a ratio of 1:1 for the 12-week treatment period. The primary objective was to demonstrate non-inferiority of salmeterol/ fluticasone vs. formoterol/budesonide, measured by mean pre-dose forced expiratory volume in the first second (FEV1), at week 12. Results This study provides evidence for the primary efficacy endpoint that salmeterol/ fluticasone was statistically as well as clinically non-inferior to formoterol/budesonide in the treatment of patients with persistent asthma. This was supported by secondary endpoints which demonstrate that salmeterol/fluticasone appeared to be comparable to formoterol/budesonide in terms of efficacy for the secondary efficacy endpoints (morning PEFR, evening PEFR, diurnal variability of PEFR, daytime and night-time asthma symptoms score, average need for short-acting ?2-agonists, proportion of patients that required rescue medication, patients with nocturnal asthma, patients without asthma symptoms of score 0 and average number of days without asthma symptoms of score 0). Salmeterol/fluticasone was safe and well tolerated; and safety profile is comparable to comparator formoterol/budesonide. Conclusion The results of this study demonstrate that HFA formulations of salmeterol/ fluticasone and formoterol/budesonide are clinically interchangeable. Overall, the study indicates that HFA-propelled salmeterol/fluticasone (50/100 mcg) pMDI was safe, well tolerated and non-inferior in efficacy compared to HFA-propelled formoterol/budesonide (6/100 mcg) pMDI." @default.
- W2621439852 created "2017-06-15" @default.
- W2621439852 creator A5019410799 @default.
- W2621439852 creator A5021111201 @default.
- W2621439852 creator A5075520078 @default.
- W2621439852 date "2016-02-20" @default.
- W2621439852 modified "2023-09-24" @default.
- W2621439852 title "A Study on Budesonide/ Formoterol vs. Fluticasone/ Salmeterol Inhaled Combination in Moderate to Severe Asthma" @default.
- W2621439852 hasPublicationYear "2016" @default.
- W2621439852 type Work @default.
- W2621439852 sameAs 2621439852 @default.
- W2621439852 citedByCount "0" @default.
- W2621439852 crossrefType "journal-article" @default.
- W2621439852 hasAuthorship W2621439852A5019410799 @default.
- W2621439852 hasAuthorship W2621439852A5021111201 @default.
- W2621439852 hasAuthorship W2621439852A5075520078 @default.
- W2621439852 hasConcept C126322002 @default.
- W2621439852 hasConcept C2776042228 @default.
- W2621439852 hasConcept C2776136866 @default.
- W2621439852 hasConcept C2776719499 @default.
- W2621439852 hasConcept C2776804153 @default.
- W2621439852 hasConcept C2777450039 @default.
- W2621439852 hasConcept C2779028295 @default.
- W2621439852 hasConcept C2779871671 @default.
- W2621439852 hasConcept C2780261241 @default.
- W2621439852 hasConcept C2781212218 @default.
- W2621439852 hasConcept C2909086917 @default.
- W2621439852 hasConcept C42219234 @default.
- W2621439852 hasConcept C71924100 @default.
- W2621439852 hasConceptScore W2621439852C126322002 @default.
- W2621439852 hasConceptScore W2621439852C2776042228 @default.
- W2621439852 hasConceptScore W2621439852C2776136866 @default.
- W2621439852 hasConceptScore W2621439852C2776719499 @default.
- W2621439852 hasConceptScore W2621439852C2776804153 @default.
- W2621439852 hasConceptScore W2621439852C2777450039 @default.
- W2621439852 hasConceptScore W2621439852C2779028295 @default.
- W2621439852 hasConceptScore W2621439852C2779871671 @default.
- W2621439852 hasConceptScore W2621439852C2780261241 @default.
- W2621439852 hasConceptScore W2621439852C2781212218 @default.
- W2621439852 hasConceptScore W2621439852C2909086917 @default.
- W2621439852 hasConceptScore W2621439852C42219234 @default.
- W2621439852 hasConceptScore W2621439852C71924100 @default.
- W2621439852 hasIssue "2" @default.
- W2621439852 hasLocation W26214398521 @default.
- W2621439852 hasOpenAccess W2621439852 @default.
- W2621439852 hasPrimaryLocation W26214398521 @default.
- W2621439852 hasRelatedWork W178083300 @default.
- W2621439852 hasRelatedWork W1990444499 @default.
- W2621439852 hasRelatedWork W1994017080 @default.
- W2621439852 hasRelatedWork W2003706075 @default.
- W2621439852 hasRelatedWork W2024265404 @default.
- W2621439852 hasRelatedWork W2041512941 @default.
- W2621439852 hasRelatedWork W2157910210 @default.
- W2621439852 hasRelatedWork W2165209634 @default.
- W2621439852 hasRelatedWork W2167462999 @default.
- W2621439852 hasRelatedWork W2313479281 @default.
- W2621439852 hasRelatedWork W2324752031 @default.
- W2621439852 hasRelatedWork W2350089776 @default.
- W2621439852 hasRelatedWork W2361710934 @default.
- W2621439852 hasRelatedWork W2366863382 @default.
- W2621439852 hasRelatedWork W2752966097 @default.
- W2621439852 hasRelatedWork W2982865571 @default.
- W2621439852 hasRelatedWork W3111031790 @default.
- W2621439852 hasRelatedWork W3196479914 @default.
- W2621439852 hasRelatedWork W3205373988 @default.
- W2621439852 hasRelatedWork W49086682 @default.
- W2621439852 hasVolume "6" @default.
- W2621439852 isParatext "false" @default.
- W2621439852 isRetracted "false" @default.
- W2621439852 magId "2621439852" @default.
- W2621439852 workType "article" @default.